Conclusion: While usage of a CGM alongside GLP-1 is still relatively low, we observed that patients using a combination of these technologies achieved better glycemic control compared to those not using CGM, likely because of increased patient feedback needed to adjust diet, exercise and other factors, as well as greater adherence to diabetes therapies
Who may qualify: Use of a covered generic drug and documented severe GI events (e.g., ER visits, hospitalizations, imaging showing delayed emptying/obstruction), especially if symptoms persisted after stopping
In particular, research is ongoing in the realm of regenerative medicine
One of AFWERXs first innovations with the program was its Open Topic approach, which allows companies with an innovative solution to pitch it without matching it to an already articulated military problem (the program has traditionally selected these research topics, sometimes with great specificity that risked inadvertently being too prescriptive in how a problem is to be solved in the solicitations)
